Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of papulopustular rosacea~* Free of any clinically significant disease, which could interfere with the study~* Male or female subject aged ≥ 18 years~* Willingness of subject to follow all study procedures~* Signed written informed consent before any study-related activities are carried out~Exclusion Criteria:~* Subjects who are known to be non-responders to azelaic acid~* Presence of dermatoses that might interfere with rosacea diagnosis~* Ocular rosacea; phymatous rosacea; subjects with plaque-type rosacea lesions, papulopustular rosacea that requires systemic treatment~* Topical use of any prescription or non-prescription medication to treat rosacea within 6 weeks prior to randomization and throughout the study~* Systemic use of any prescription or non-prescription medication to treat rosacea (Retinoids within 6 months, Tetracycline within 2 months, Corticosteroids, erythromycin, azithromycin, and/or metronidazole within 4 weeks) prior to randomization and throughout the study~* Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization~* Known hypersensitivity to any ingredients of the investigational product formulation~* Participation in another clinical research in parallel or within the last 4 weeks before randomization in this study~* Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelaic acid foam, 15% (BAY39-6251) (Type: EXPERIMENTAL): 0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
- Vehicle foam (Type: PLACEBO_COMPARATOR): 0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).